The American Journal of Surgery
Volume 187, Issue 1 , Pages 39-46 , January 2004

Management of neuroendocrine liver metastases

  • Robert Sutcliffe

      Affiliations

    • Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • ,
  • Donal Maguire, M.D.

      Affiliations

    • Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • ,
  • John Ramage, M.D.

      Affiliations

    • Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • ,
  • Mohamed Rela

      Affiliations

    • Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • ,
  • Nigel Heaton

      Affiliations

    • Institute of Liver Studies, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44-20-7346-3575; fax: +44-20-7346-3575.

Received 12 November 2002 ,Revised 7 April 2003

References 

  1. Benevento A, Boni L, Frediani L, et al.  Result of liver resection as treatment for metastases from noncolorectal cancer. J Surg Oncol. 2000;74:24–29
  2. Chamberlain RS, Canes D, Brown KT, et al.  Hepatic neuroendocrine metastases (does intervention alter outcomes?). J Am Coll Surg. 2000;190:432–445
  3. Ihse I, Persson B, Tibblin S. Neuroendocrine metastases of the liver. World J Surg. 1995;19:76–82
  4. Moertel GC. An odyssee in the land of small tumours. J Clin Oncol. 1987;5:1503
  5. Soreide O, Berstad T, Bakka A, et al.  Surgical treatment as a principle in patients with advanced abdominal carcinoid tumours. Surgery. 1992;111:726
  6. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation. 1998;66:1307–1312
  7. Modlin IM, Sandor A. An analysis of 8,305 cases of carcinoid tumours. Cancer. 1997;79:813–829
  8. Newton JN, Swerdlow AJ, dos Santos Silva IM, et al.  The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer. 1994;70:939–942
  9. Dotzenrath C, Goretzki PE, Cupisti K, et al.  Malignant endocrine tumors in patients with MEN 1 disease. Surgery. 2001;129:91–95
  10. Chandrasekharrappa SC, Guru SC, Manickam P, et al.  Positional cloning of the gene of multiple endocrine neoplasia-type 1. Science. 1997;276:404–407
  11. Harvey M, Vogel H, Lee EYHP, et al.  Mice deficient in both p53 and Rb develop tumours primarily of endocrine origin. Cancer Res. 1995;55:1146–1151
  12. Höfler H, Ruhri C, Putz B, et al.  Oncogene expression in endocrine pancreatic tumours. Virchows Arch B Cell Path. 1988;55:355–361
  13. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand. 1976;84:322–323
  14. Crocetti E. Gastrointestinal carcinoid tumours. A population-based study. Ital J Gastroenterol Hepatol. 1997;29:135–137
  15. Phan GQ, Yeo CJ, Hruban RH, et al.  Surgical experience with pancreatic and peripancreatic neuroendocrine tumors (review of 125 patients). J Gastrointest Surg. 1998;2:472–482
  16. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl 1):33–38
  17. Pape U-F, Hocker M, Seuss U, Wiedenmann B. New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system. Recent Res Cancer Res. 2000;153:45–60
  18. Wick MR. Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol. 2000;113:331–335
  19. Rindi G, Capella C, Solcia E. Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract. Q J Nucl Med. 2000;44:13–21
  20. Rindi G, Azzoni C, La Rosa S, et al.  ECL cell tumour and poorly differentiated endocrine carcinoma of the stomach (prognostic evaluation and outcome prediction by pathological analysis). Gastroenterology. 1999;116:532–542
  21. Pipeleers-Marichal M, Somers G, Willems G, et al.  Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med. 1990;322:723–727
  22. Heymann MF, Joubert M, Nemeth J, et al.  Prognostic and immunohistochemical validation of the Capella classification of pancreatic neuroendocrine tumours (an analysis of 82 sporadic cases). Histopathology. 2000;36:421–432
  23. Oliaro A, Donati G, Filosso PL, Ruffini E. Neuroendocrine tumors of the lung. [translation] Minerva Chir. 2000;55:7–16
  24. Chiti A, Fanti S, Savelli G, et al.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25:1396–1403
  25. Joseph K, Stapp J, Reinecke J, et al.  Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Horm Metab Res. 1993;27(suppl):28–35
  26. Krenning EP, Kwekkeboom DJ, Bakker WH, et al.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]- octreotide (the Rotterdam experience with more than 1000 patients). Eur J Nucl Med. 1993;20:716–731
  27. Zimmer T, Ziegler K, Bäder M, et al.  Localization of neuroendocrine tumours of the upper gastrointestinal tract. Gut. 1994;35:471–475
  28. Zimmer T, Stolzel U, Bader M, et al.  Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Gut. 1996;39:562–568
  29. Gibril F, Reynolds JC, Doppman JL, et al.  Somatostatin receptor scintigraphy (its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study). Ann Intern Med. 1996;125:26–34
  30. Frucht H, Doppman JL, Norton JA, et al.  Gastrinomas (comparison of MR imaging with CT, angiography, and US). Radiology. 1989;171:713–717
  31. Doppman JL, Jensen RT. Localization of gastroenteropancreatic tumours by angiography. Ital J Gastroenterol Hepatol. 1999;31(suppl 2):S163–166
  32. Anderson MA, Carpenter S, Thompson NW, et al.  Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95:2271–2277
  33. Anthuber M, Jauch KW, Briegel J, et al.  Results of liver transplantation for gastroentreopancreatic tumor metastases. World J Surg. 1996;20:73–76
  34. Wiedenmann B, Bader HM, Scherubl H, et al.  Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy. Semin Oncol. 1994;21(suppl 13):29–32
  35. Nicholson SA, Ryan MR. A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation. Cancer. 2000;90:148–161
  36. Lang H, Schlitt HJ, Schmidt H, et al.  Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas—a single center experience with ten patients. Langenbecks Arch Surg. 1999;384:370–377
  37. Schweizer RT, Alsina AE, Rosson R, Bartus SA. Liver transplantation for metastatic neuroendocrine tumours. Transplant Proc. 1993;25:1973
  38. Routley D, Ramage JK, McPeake J, et al.  Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver. Liver Transpl Surg. 1995;1:118–121
  39. Coperchini ML, Jones R, Angus P, et al.  Liver transplantation in metastatic carcinoid tumour. Aust NZ J Med. 1996;26:702–704
  40. Le Treut YP, Delpero JR, Dousset B, et al.  Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225:355–364
  41. Dousset B, Houssin D, Soubrane O, et al.  Metastatic endocrine tumors (is there a place for liver transplantation?). Liver Transpl Surg. 1995;1:111–117
  42. Knechtle SJ, Kalayoglu M, D'Alessandro AM, Rikkers LF. Proceed with caution (liver transplantation for metastatic neuroendocrine tumors). Ann Surg. 1997;225:345–346
  43. Lang H, Oldhafer KJ, Weimann A, et al.  Liver transplantation for metastatic neuroendocrine tumors. Ann Surg. 1997;225:347–354
  44. Coppa J, Pulvirenti A, Schiavo M, et al.  Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplant Proc. 2001;33:1537–1539
  45. Gulanikar AC, Kotylak G, Bitter-Suermann H. Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation?. Transplant Proc. 1991;23:2197–2198
  46. Tsushima K, Nagorney DM, Weiland LH, Lieber MM. The relationship of flow cytometric DNA analysis and clinicopathology in small intestine carcinoids. Surgery. 1989;105:366–373
  47. Grazi GL, Cescon M, Pierangeli F, et al.  Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology. 2000;47:481–486
  48. Chen H, Hardcare JM, Uzar A, et al.  Isolated liver metastases from neuroendocrine tumours (does resection prolong survival?). J Am Coll Surg. 1998;187:88–93
  49. Que FG, Nagorney DM, Batts KP, et al.  Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995;169:36–42
  50. Hemming AW, Sielaff TD, Gallinger S, et al.  Hepatic resection of noncolorectal nonneuroendocrine metastases. Liver Transpl. 2000;6:97–101
  51. Doci R, Gennari L, Gignami P, et al.  One hundred patients with hepatic metastases from colorectal cancer treated by resection (analysis of prognostic determinants). Br J Surg. 1991;78:797–801
  52. Registry of Hepatic Metastases . Resection of the liver for colorectal carcinoma metastases (a multiinstitutional study for indication of resection). Surgery. 1988;103:278–288
  53. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumours. Surgery. 1992;112:1024–1032
  54. Ahlman H, Wangberg B, Jansson S, et al.  Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion. 2000;62(suppl 1):59–68
  55. Eriksson BK, Larsson EG, Skogseid BM, et al.  Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998;83:2293–2301
  56. Brown KT, Koh BY, Brody LA, et al.  Particle embolization of hepatic metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol. 1999;10:397–403
  57. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues (a review). Digestion. 2000;62(suppl 1):84–91
  58. Oberg K. Endocrine tumors of the gastrointestinal tract (systemic treatment). Anticancer Drugs. 1994;5:503–519
  59. Ricci S, Antonuzzo A, Galli L, et al.  Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23:412–415
  60. Ricci S, Antonuzzo A, Galli L, et al.  Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127–1130
  61. Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol. 1999;31(suppl 2):S216–218
  62. Eriksson B, Renstrup J, Imam H, Öberg K. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors (clinical and biological effects). Ann Oncol. 1997;8:1041–1044
  63. Faiss S, Rath U, Mansmann U, et al.  Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999;60:469–476
  64. di Bartolomeo M, Bajetta E, Buzzoni R, et al.  Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77:402–408
  65. De Jong M, Breeman WA, Bernard HF, et al.  Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. Q J Nucl Med. 1999;43:356–366
  66. Mukherjee JJ, Kaltsas GA, Islam N, et al.  Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf). 2001;55:47–60
  67. Castellani MR, Chiti A, Seregni E, Bombardieri E. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan. Q J Nucl Med. 2000;44:77–87
  68. Chatal JF, Le Bodic MF, Kraeber-Bodere F, et al.  Nuclear medicine applications for neuroendocrine tumors. World J Surg. 2000;24:1285–1289
  69. Moertel CG, Lefkopoulo M, Lipsitz S, et al.  Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–523
  70. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol. 1998;21:36–38
  71. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion. 2000;62(suppl 1):79–83
  72. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery. 1994;116:1111–1116
  73. Dominguez S, Denys A, Madeira I, et al.  Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000;12:151–157
  74. Kim YH, Ajani JA, Carrasco CH, et al.  Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest. 1999;17:474–478
  75. Oberg K. Interferon in the management of neuroendocrine GEP-tumors (a review). Digestion. 2000;62(suppl 1):92–97
  76. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect?. Eur J Haematol. 1997;59:129–135
  77. Bilchik AJ, Rose DM, Allegra DP, et al.  Radio-frequency ablation (a minimally invasive technique with multiple applications). Cancer J Sci Am. 1999;6:356–361
  78. Siperstein A, Garland A, Engle K, et al.  Laparoscopic radiofrequency ablation of primary and metastatic liver tumors. Technical considerations. Surg Endosc. 2000;14:400–405
  79. Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery. 1997;122:1147–1154
  80. Maguire D, O'Sullivan GC, Collins JK, et al.  Bone marrow micrometastases and gastrointestinal cancer detection and significance. Am J Gastroenterol. 2000;95:1644–1651
  81. Shebani KO, Souba WW, Finkelstein DM, et al.  Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999;229:815–823

PII: S0002-9610(03)00455-0

doi: 10.1016/j.amjsurg.2003.04.007

The American Journal of Surgery
Volume 187, Issue 1 , Pages 39-46 , January 2004

Article Tools

* Image Usage & Resolution